Trading Day Triumph: Prime Medicine Inc (PRME) Ends at 5.99, a -2.60 Surge/Plunge

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Prime Medicine Inc (NASDAQ: PRME) closed the day trading at $5.99 down -2.60% from the previous closing price of $6.15. In other words, the price has decreased by -$2.60 from its previous closing price. On the day, 2.15 million shares were traded. PRME stock price reached its highest trading level at $6.2309 during the session, while it also had its lowest trading level at $5.875.


For a better understanding of PRME, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.91 and its Current Ratio is at 8.91. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.15.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on May 20, 2024, initiated with a Buy rating and assigned the stock a target price of $10.

On May 16, 2024, Citigroup Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $10.

On April 22, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $17.Chardan Capital Markets initiated its Buy rating on April 22, 2024, with a $17 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 15 ’24 when ARCH Venture Partners XII, LLC bought 3,200,000 shares for $6.25 per share. The transaction valued at 20,000,000 led to the insider holds 3,200,000 shares of the business.

ARCH Venture Partners X, LLC bought 3,200,000 shares of PRME for $20,000,000 on Feb 15 ’24. The 10% Owner now owns 3,200,000 shares after completing the transaction at $6.25 per share. On Feb 15 ’24, another insider, NELSEN ROBERT, who serves as the Director of the company, bought 3,200,000 shares for $6.25 each. As a result, the insider paid 20,000,000 and bolstered with 3,200,000 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 718985664 and an Enterprise Value of 525661664. For the stock, the TTM Price-to-Sale (P/S) ratio is 1218.61 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at 889.444 whereas that against EBITDA is -2.7.

Stock Price History:

Over the past 52 weeks, PRME has reached a high of $15.75, while it has fallen to a 52-week low of $4.11. The 50-Day Moving Average of the stock is -1.98%, while the 200-Day Moving Average is calculated to be -20.89%.

Shares Statistics:

Over the past 3-months, PRME traded about 844.07K shares per day on average, while over the past 10 days, PRME traded about 1019430 shares per day. A total of 97.38M shares are outstanding, with a floating share count of 50.59M. Insiders hold about 57.85% of the company’s shares, while institutions hold 34.66% stake in the company. Shares short for PRME as of 1715731200 were 11251663 with a Short Ratio of 13.57, compared to 1713139200 on 10213643. Therefore, it implies a Short% of Shares Outstanding of 11251663 and a Short% of Float of 19.690001.

Most Popular